CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD

CSM Advisors LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 73.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,075 shares of the biopharmaceutical company’s stock after selling 42,400 shares during the quarter. CSM Advisors LLC’s holdings in Gilead Sciences were worth $1,674,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trivium Point Advisory LLC raised its position in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares during the period. Binnacle Investments Inc lifted its stake in shares of Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 83 shares in the last quarter. Rothschild Investment LLC boosted its holdings in Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the period. Hemington Wealth Management boosted its holdings in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares during the period. Finally, Ignite Planners LLC grew its stake in Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after buying an additional 86 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $145.21 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a fifty day moving average of $141.16 and a 200-day moving average of $127.19. The company has a market capitalization of $180.27 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.90 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The firm’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 303,280 shares of company stock valued at $43,203,470. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Rothschild & Co Redburn increased their target price on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Oppenheimer boosted their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.